Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 4.7% - Should You Sell?

Key Points

• Shares of Arcturus Therapeutics (NASDAQ:ARCT) experienced a decline of 4.7% in mid-day trading, with a last recorded price of $21.50, down from a previous close of $22.56.
• Analysts have mixed ratings on the stock, with price targets ranging from $42.00 to $63.00, and a consensus rating of "Moderate Buy" based on reports from multiple firms.
• Arcturus Therapeutics reported better-than-expected quarterly earnings of ($0.34) per share, surpassing analysts' estimates, and generated revenue of $28.30 million against expectations of $17.64 million.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report)'s stock price dropped 4.7% during mid-day trading on Monday . The company traded as low as $21.40 and last traded at $21.50. Approximately 388,162 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 503,747 shares. The stock had previously closed at $22.56.

Wall Street Analyst Weigh In

ARCT has been the topic of a number of recent analyst reports. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Leerink Partners cut their target price on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating on the stock in a research report on Friday, August 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Saturday, September 27th. Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Citigroup reiterated a "buy" rating and set a $49.00 target price (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Arcturus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.57.

Arcturus Therapeutics Price Performance

The stock's fifty day simple moving average is $17.19 and its 200-day simple moving average is $13.96. The stock has a market cap of $570.53 million, a P/E ratio of -9.42 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.11) by $0.77. The business had revenue of $28.30 million for the quarter, compared to analysts' expectations of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. Analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ARCT. Osaic Holdings Inc. boosted its holdings in shares of Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 738 shares in the last quarter. Byrne Asset Management LLC lifted its position in Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 1,365 shares during the period. US Bancorp DE boosted its stake in Arcturus Therapeutics by 218.9% during the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,329 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Arcturus Therapeutics by 163.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 2,586 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Arcturus Therapeutics by 3,482.9% during the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after purchasing an additional 5,085 shares during the period. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.